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Abstract 
Identifying Progenitor Cells of Heterotopic Ossification 
Eileen Semancik, University Scholars and Honors Programs 
University of Connecticut 
2012 
Heterotopic Ossification (HO) is the abnormal formation of bone within 
extraskeletal soft tissues.  The condition can occur through both genetic and acquired 
means.  Acquired cases of HO result from invasive surgery or traumatic injuries, with 
increasing prevalence of ectopic skeletogenesis as a result of combat-related blast injuries.  
HO has been characterized to some extent, including the histological features and the 
mutation underlying the genetic form, but the cells resident in skeletal muscle that 
represent the progenitors of heterotopic bone have yet to be determined. Only a few 
publications have attempted to definitively determine the progenitor cells in this disorder.  
Findings have been inconclusive, but cell types such as skeletal muscle satellite cells, 
pericytes and endothelial cells, mesenchymal progenitors, and circulating hematopoietic 
cells were considered attractive candidates due to accessibility and displays of osteogenic 
characteristics.  The aim of this study was to determine the progenitor cells of HO.  To 
accomplish this goal, lineage tracing and bioassays of heterotopic ossification were used 
to identify and characterize the progenitor cell type.  We identified a population of Tie2+ 
cells that are non-endothelial (CD31-) in origin and represent a major source of 
progenitors for HO. The identification of the progenitor is crucial to establishing any 
future therapeutic agents or treatments for HO.   
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Introduction 
I. Heterotopic Ossification and Fibrodysplasia Ossificans Progressiva 
During embryonic development, the skeleton develops from undifferentiated 
mesenchyme according to a precise temporal and spatial genetic plan.  Postnatally, 
however, bone formation is restricted to fracture sites (Sharitz, et al., 1996).  
Heterotopic ossification (HO) results from abnormal regulation of this process.   
HO is the formation of lamellar bone inside the soft-tissue structures in 
which bone does not normally exist (Bossche & Vanderstraeten, 2005).  HO exists in 
both acquired and hereditary forms.  The condition occurs in its acquired form as a 
complication following central nervous system disorders, multiple injuries, hip 
surgeries, burns, and in trauma and combat wounds (Bossche & Vanderstraeten, 
2005; Potter 2007). Historically, HO was first documented in the medical literature 
in 1736 (Kaplan, et al., 2008), and has been noted in combat-related injuries in the 
American Civil War and World War I (Potter 2007).    
Hereditary forms have also been identified, the most notable of which is a 
condition called fibrodysplasia ossificans progressiva (FOP) (Kaplan, et al., 2008).  
FOP is a rare, disabling genetic condition in which congenital skeletal malformations 
and progressive HO form in sites including skeletal muscle, tendon, ligament, and 
fascia (Kaplan, et al., 2009).  FOP can be inherited in an autosomal dominant fashion, 
although most cases are spontaneous in origin (Kaplan, et al., 2008).   This is the 
most disabling form of HO in humans, characterized by multiple and sporadic flare-
 8 
ups from soft-tissue injury (e.g.. intramuscular injections) that ultimately lead to 
musculoskeletal immobility (Kaplan, et al., 2008). Clinically, FOP is characterized by 
a congenital malformation of the big toe observed at birth and the aforementioned 
heterotopic osteogenesis in predictable anatomical patterns (Kan, et al., 2004).  By 
early adulthood, HO typically leads to ankylosis of all major joints of the axial and 
appendicular skeleton. As a result, movement is slowly hindered and eventually 
impossible, requiring lifelong assistance in performing activities of daily living 
(Sharitz, et al., 1996).  
Soft tissue injury has been demonstrated to lead to the increased expression 
of BMP4 and other osteogenic cytokines, which has, in turn, lead to a proposed 
mechanism for HO.  BMPs are a family of highly conserved extracellular signaling 
proteins that regulate cell differentiation fates (Kaplan, et al., 2009).  One role of 
BMPs is as bone-inducing morphogens that participate in the developmental 
organization of the skeleton (Sharitz, et al., 1996).  Both type I and II BMP receptors 
are serine/threonine kinases with similar functional domains.  Following activation 
via ligand binding to the receptor in the GS domain of the type II receptor, the 
transmembrane serines and threonines of the type I receptor are phosphorylate, 
activating the BMP type I receptor to transmit BMP signals (Sharitz, et al., 1996).  
This signaling is mediated through three known type I receptors, including the 
activin A type I receptor/activin-like kinase 2 (ACVR1/ALK2) receptor (Sharitz, et 
al., 1996).  Activated BMP type I receptor kinase activity phosphorylates receptor 
regulated Smad1, Smad5, and Smad8.  These then form heteromeric complexes with 
Smad4 and translocate into the nucleus to regulate transcription of various target 
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genes (Fukuda, et al., 2009).  Inhibitory Smads, including Smad6 and Smad7, are also 
induced by BMPs; these function as a negative feedback loop that down regulates 
BMP signaling through inhibition (Fukuda, et al., 2009) 
FOP patients develop an ectopic skeleton because of dysregulation of BMP 
signaling in the presence of inflammatory triggers (Lounev, et al., 2009).  Through 
familial studies, it was discovered that all patients who exhibit classic clinical 
features of FOP have the same heterozygous mutation in the ACVR1/ALK2 receptor, 
one of the aforementioned BMP type I receptors (Kaplan, et al., 2009).   Specifically, 
this mutation is found in the glycine and serine residue (GS) activation domain and 
results in arginine replaced with histidine in codon 206, altering the receptor 
signaling activity (Kaplan, et al., 2009). Functional analysis has also demonstrated 
that this mutation induces increased BMP signaling in a ligand independent and 
BMP responsive manner (Fukuda, et al., 2009). This may be through Smad1 or 
Smad5, which increase following injury and further enhance BMP signaling that is 
already stimulated by a constitutively active ALK2 receptor mutation (Fukuda, et al., 
2009). 
II. Animal Models of Heterotopic Ossification  
 Animal models of HO are necessary in order to best represent the 
pathophysiology in a practical setting for experimentation and laboratory 
manipulation.  As research and knowledge progress, animal models of HO will 
continue to be important for the opportunity to better understand the biology of 
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these conditions and to study the effectiveness and safety of currently available and 
emerging therapies, prior to human application (Kaplan, et al., 2008).   
BMPs induce heterotopic bone formation through the classic endochondral 
ossification pathway.  In HO lesions, this pathway begins with an early 
fibroproliferative phase, which is then followed by chondrocyte differentiation.  
Next, vascularization occurs, followed by osteoblast differentiation with bone matrix 
formation, and finally mineralization of the osteoid (O'Connor, 1996).  The 
osteogenic response that occurs in HO has been characterized in detail by multiple 
groups (Lounev, et al., 2009).  At present, animal models exist that emulate the 
induction of HO through this same endochondral ossification pathway—BMP 
injection (Lounev, et al., 2009) and over-expression of BMPs using the Nse 
transgenic mouse line (Kan, et al., 2004).  Both models of HO recapitulate 
characteristic features of common acquired forms of HO (Lounev, et al., 2009).   A 
genetic model of FOP has just recently been published that recapitulates this genetic 
form (Chakkalakal, et al., 2012).  
 The BMP injection model recapitulates the phenotype of acquired HO via a 
lesion that follows the classical endochondral ossification pathway.  Growth factor-
reduced Matrigel is impregnated with recombinant human BMP2 and either injected 
directly into the leg musculature, or implanted into subcutaneous sites of adult mice 
(Lounev, et al., 2009).   At physiological temperatures, the BMP2 infused-Matrigel 
solidifies to form a localized source of BMPs (Lounev, et al., 2009).  The heterotopic 
lesion is recovered for analysis 4 days to 2 weeks following implantation.  
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 In the Nse transgenic mice, the BMP4 gene is ectopically expressed at the 
neuromuscular junction under the control of the neuron-specific enolase (Nse) 
promoter, leading to progressive HO (Kan, et al., 2004).  HO is induced in these mice 
via muscle injury by injecting cardiotoxin into the quadriceps muscle (Kan, et al., 
2004).  Analysis can be performed on the tissue at various points after injection.   
 The most recent animal model is a genetic model, which used gene-targeting 
methods to develop a knock-in mouse model with the R206H mutation in ACVR1 
found in FOP patients.  This mouse’s phenotype recapitulates identifying 
characteristics of FOP in humans, including malformed first digits in the hind limbs 
and post-natal extra-skeletal bone formation (Chakkalakal, et al., 2012).  In addition 
to providing another mechanism for future research into FOP, this mouse provides 
the first in vivo evidence that the mutation in the BMP type I receptor ACVR1/ALK2 
is the direct genetic cause of FOP (Chakkalakal, et al., 2012).   
III. Potential Progenitor Cells  
 Ultimately, HO research aims to develop treatments that will prevent, halt, or 
someday even reverse the progression of the condition (Kaplan, et al., 2008).   
Although the mutation responsible for FOP is known, this is merely the proximate 
genetic cause—the cells that respond by forming bone in acquired and genetic 
forms remain unidentified.   Determination of the lineage of cells responsible for HO 
will provide cellular and molecular mechanisms relevant to this condition. An 
understanding of the cellular basis of these conditions is necessary to further 
research.  
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Although the particular cells have remained elusive, a number of groups have 
speculated as to a variety of potential progenitor cells of the HO. Speculation of 
potential progenitors has included tissue-resident skeletal muscle stem cells 
(satellite cells), endothelial precursors, vascular smooth muscle, circulating 
osteoprogenitors, and multipotent mesenchymal cells (Lounev, et al., 2009).   
 In order to trace and model the contributions of these various cells, many 
groups employ the Cre/loxP system.  Both the BMP injection and Nse transgenic 
mouse models can be used in combination with the Cre/loxP system. Mice 
expressing Cre recombinase under a cell-specific promoter are crossed to mice in 
which a reporter gene is separated from a constitutively active promoter by stop 
sequences, surrounded by loxP sites.  LoxP sites are DNA sequences containing 
specific binding sites where Cre cuts and recombines the DNA, which ensures the 
reporter gene is transcribed, providing permanent, Cre-dependent expression and 
cell-specific labeling (Lounev, et al., 2009).  This is a cell tracing method in mice used 
to identify cell lineages; in HO experiments, the contribution of labeled cells to 
fibroproliferative lesions, cartilage, and bone can be evaluated using histological 
methods (Lounev, et al., 2009).  According to recent characterizations in the 
literature, cell-specific promoters of interest include the following: Tie2-Cre, to label 
vasculature and hematopoietic stem cells; MyoDiCre, to label muscle and muscle 
satellite cells; and SM22Cre, to label pericytes and smooth muscle (Lounev, et al., 
2009; Medici, et al., 2010).  
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  Many groups have debated whether the progenitor cells are local, residing 
within the skeletal muscle and associated soft tissues, or are from a more widely 
distributed cell progenitors that are osteogenic within the conditions provided by 
the muscle.  Although there is much speculation into circulating osteogenic 
progenitors, bone marrow transplantation has contributed conflicting data 
regarding the contribution of circulating cells.   In addition, lineage tracing in 
transgenic mice did not detect a direct cellular contribution of cells of a 
hematopoietic lineage (Kaplan, et al., 2007).  However, these findings conflict with 
those of other groups, such as Suda, et al. (Suda, et al., 2009), previous lineage 
tracing (Otsuro, et al., 2007), and parabiosis (Otsuro, et al., 2008) studies which 
have found that the osteogenic progenitor cells were blood-derived.  These blood-
derived progenitors were shown to contribute to heterotopic bone in BMP2-induced 
osteogenesis, as well as to exist as osteogenic progenitors in culture experiments 
(Otsuro, et al., 2007).  The same group confirmed there results further in parabiotic 
experiments, demonstrating that ~50% of all osteoblasts were derived from 
osteogenic progenitors that were marrow-derived (Otsuro, et al., 2008).      
On the other hand, a tissue resident cell of interest, muscle-specific stem cells, 
has also been a target as a progenitor for heterotopic lesions, as they have 
demonstrated osteogenic capabilities in cell culture.  Once again though, lineage-
tracing experiments by Lounev, et al. have demonstrated that satellite cells do not 
significantly contribute to HO (Lounev, et al., 2009).  
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Vascular endothelium has become the leading candidate for the progenitor cell 
source of heterotopic lesions.  In recent work by Medici et al., endothelial cells have 
demonstrated both osteogenic activity and multipotency (Medici, et al., 2010).  
However, it is important to note that the Cre used in these experiments lacked 
stringent lineage specificity.  In past studies, cells expressing Tie2 have been 
demonstrated to contribute to all stages of BMP2-induced heterotopic lesions, 
though the endothelial origin must be evaluated further because, although 
endothelium is the predominant cell type labeled by transgenic Tie2Cre; R26NG/+ 
mice, Tie2 is expressed in many non-endothelial cell types (Lounev, et al., 2009; 
Medici, et al., 2010). 
Lineage tracing and bioassays were used to identify the progenitor cell of HO.  In 
these experiments, we demonstrate that endothelial cells do not significantly 
contribute to HO in mouse models, and that Tie2+, non-endothelial cells resident in 
the skeletal muscle interstitium are the predominant source of progenitor cells of 
heterotopic lesions.  
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Materials & Methods 
I. Mouse Models and Genotyping 
Tie2-Cre transgenic mice, SCID transgenic mice, and R26NG Cre-dependent GFP 
reporter mice were obtained for use in these experiments.  Experimental mice 
carried the Cre transgene and were heterozygous for the necessary reporter allele.  
Genotypes were verified via PCR and through observation of reporter fluorescence.  
Tissue-specific recombination was verified at the time of tissue harvesting.  All 
animal procedures were reviewed and approved by the University of Connecticut’s 
Institutional Animal Care and Use Committee under the Goldhamer laboratory 
protocol.  
Tails were obtained by taking a small tail clip with the mice under general 
anesthesia using isoflurane.  Tail clippings were processed for DNA extraction by 
initially digesting them in a mixture of 20 mg/ml of proteinase K and tail buffer 
overnight at 55°C.  Each sample was then incubated at 37°C for one hour after 
adding 10 mg/ml of RNase A.  After spinning down the samples, the lysate 
suspension was added to a mixture of QX1 buffer and diatomaceous earth.  After 
two minutes, Merlin V was added, the samples were spun down, and the 
supernatant was removed.  This was repeated, and the particulate was allowed to 
dry.  The purified DNA particle was finally resuspended in 65°C TE buffer and stored 
at 4°C for further use.  DNA samples were genotyped by PCR amplification and 
visualized using agarose gel electrophoresis, with an ~ 479 bp product expected if 
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the Tie2 promoter driven Cre gene was present.  Primers used for Tie2Cre PCR 
were: forward 5’- CCCTGTGCTCAGACAGAAATGAGA- 3’, and reverse  
5’- CGCATAACCAGTGAAACACGATTGC- 3’. 
II. Tissue Preparation 
Muscles and lesional tissue were isolated via dissection and fixed in 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 3-6 hours at 4°C 
with gentle agitation, washed with PBS, and then cryo-protected overnight in 30% 
sucrose at 4°C overnight with gentle agitation.  The samples were then embedded in 
O.C.T. and frozen in cooled pentanes. Tissue samples were cryostat sectioned in 
12μm sections and collected on glass slides.  Samples and subsequently sectioned 
tissues were stored at -80°C until further use.  
III. Immunofluorescence and Histochemistry (IHC) 
For CD31, Osterix, and Sox9 staining, sections were rehydrated in PBS, 
permeabilized in 0.1% Triton in PBS, blocked in 1% bovine serum albumin (BSA), 
10% goat serum, and 0.1% Tween in PBS.   They were then stained with primary 
antibody in PBS containing 10% goat serum and 1% BSA overnight at 4°C.  The 
samples were then washed in PBS, stained with a flour conjugated secondary 
antibody at room temperature for 1.5-2 hours, washed in PBS, stained with DAPI 
and cover-slipped.  
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IV. Fluorescence Activated Cell Sorting (FACS) and Cell Transplantation 
Total hind limb muscle was isolated via dissection and minced for 7 minutes 
with scissors.  The tissue was then transferred to a conical containing Collagenase 
and Dispase in DMEM.  The conical was incubated in a 37°C water bath for 60-85 
minutes with trituration every 15 minutes.  To end the digestion, 20% FBS in DMEM 
was added.  The sample was filtered through 100 μm and 70 μm cell strainers.  After 
centrifugation, the sample was washed with PBS and re-suspended in 10% fetal 
bovine serum (FBS) in PBS.  The sample cells were then incubated with 
fluorescently conjugated antibodies (CD31) at 4°C for 30 minutes.  The cells were 
washed with PBS, collected by centrifugation, and re-suspended in 2% FBS.  Cells 
were placed on ice until analysis and sorting.  The cells were then filtered through 
30μm cell strainer and propidium iodine was added.   Sorting and analysis was then 
performed using a FACS machine.  
Cell populations from the FACS sort were washed with PBS chilled on ice.  These 
were collected via centrifugation and resuspended in Matrigel containing BMP2.  
The cell suspension was injected into the tibialis anterior (TA) hindlimb muscle of 
SCID mice using an insulin syringe.  At 10.5 days post-injection, the TA muscle was 
isolated and fixed as described.  
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Results 
I. Mouse Models 
The primary aim of this study was to determine the progenitor cell type in HO.  
This required the Tie2-Cre transgenic mice, which labels vasculature and 
hematopoietic stem cells, because past studies have shown cells expressing this 
marker contributing to heterotopic lesions (Lounev, et al., 2009; Medici, et al., 2010; 
Wosczyna, et al., 2012).  In addition, this required the R26NG Cre-dependent GFP 
reporter mice, and immunodeficient (SCID) mice.  We employed the Cre/loxP 
system to label cells and trace the contribution of Tie2+ cells to HO lesional tissue, 
providing permanent, Cre-dependent expression and cell-specific labeling (Lounev, 
et al., 2009). Using a bioassay of HO, reporter cell contribution to the cartilage and 
bone of fibroproliferative lesions was evaluated using histological methods 
described in later subsections. 
Experimental mice possessed the Cre transgene and were heterozygous for the 
necessary reporter allele.  Genotypes were verified via PCR analysis of DNA from tail 
clippings (Fig. 1) and through observation of reporter fluorescence of the same tail 
clippings, prior to DNA extraction (Fig. 2).  A ~ 479 bp product was present in the 
gel electrophoresis of the PCR products when the Tie2 promoter driven Cre gene 
was present, as demonstrated by the columns in the example in Fig. 1.   These are 
labeled with a +, consistent with the known positive control (labeled), while a 
negative example is listed, labeled with a –, and has no band present.  The mice 
determined to be positive for both transgenes were used in further experiments.  
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           CONTROLS 
          +   +   +   +    -   +   -  
     
Fig. 1 Image of genotyping results by PCR and gel electrophoresis to verify Tie2Cre; R26NG/+ 
recombination.  Columns with a + represent mice positive for the reporter, as they have a band at 
~479 bp consistent with the known Tie2-Cre control, also marked with a  +.  The column marked 
with a – represents a mouse negative for the reporter, consistent with the known negative control. 
   A      B 
  
Fig. 2 Fluorescence microscopy image of a Tie2Cre; R26NG/+ - mouse-tail clip.  In both images, the 
left side is a negative mouse, and the positive is on the right in green. (A) A mouse-tail clip with skin 
and (B) a mouse-tail clip with the skin removed for better visibility of fluorescence. 
II. Endothelial Labeling in the Tie2-Cre;Reporter Mouse 
Past studies have demonstrated cells expressing Tie2 contribute to all stages of 
BMP2-induced heterotopic lesions, but have conflicted in their determination of the 
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endothelial origin of these potential progenitor cells (Lounev, et al., 2009; Medici, et 
al., 2010; Wosczyna, et al., 2012).  Although endothelium is the predominant cell 
type labeled by transgenic Tie2Cre; R26NG/+ mice, Tie2 is expressed in many non-
endothelial cell types.   
We first established the efficiency of the Cre reporter to label endothelium using 
immunohistochemistry (IHC).  Using the endothelial marker, CD31, we estimated 
the labeling efficiency by co-localization with GFP cells.  Nearly 100% of the CD31+ 
cells were also GFP+ (Fig. 3), proving highly efficient Cre-dependent endothelial cell 
labeling.  
 
Fig. 3 Cre/loxP labeling with the Tie2 reporter efficiently labels endothelial cells.  
Immunohistochemistry on TA muscle from Tie2-Cre; R26NG/+ mice using an endothelial marker 
(CD31) demonstrates this, as nearly 100% of the cells that are labeled with CD31 co-localize with 
GFP fluorescence. (Wosczyna et. al, 2012) 
Next, cells were obtained from the total hind limb musculature of Tie2-Cre; 
R26NG/+ mice by fluorescence-activated cell sorting (FACS); they were sorted for the 
expression of GFP and CD31.  The cell populations were isolated in two groups, 
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GFP+/CD31+ (Fig. 4, population A in blue) and GFP+/CD31- (Fig. 4B, population B in 
red), representing Tie2+ cells that are endothelial and non-endothelial in origin, 
respectively. 
 
Fig. 4 FACS analysis sorting the total hind limb muscles from Tie2-Cre; R26NG/+ mice into two 
populations: (A) GFP+/CD31+ (endothelial) and (B) GFP+/CD31- (non-endothelial). These 
populations were collected for analysis using a heterotopic osteogenesis bioassay to determine the 
extent of their contribution to the lesional tissue. (Wosczyna et. al, 2012) 
   
III. Heterotopic Osteogenesis Bioassay   
  
Fig. 5  Schematic of the intramuscular transplantation experimental design. (Wosczyna et. al, 2012) 
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The capacity of GFP+/CD31+ and GFP+/CD31- cells to participate in HO was 
assessed using cell transplantation experiments, followed by immunofluorescence 
analysis by IHC.  Figure 5 is a schematic of the experimental design.  To test for 
osteogenic activity, the two populations of cells were each mixed with 
BMP2/Matrigel and injected into the mid-belly of the TA muscle of SCID mice.  The 
lesional tissue was harvested 10.5d post-injection.  Fig 6 displays an example of the 
histology of a BMP2-induced heterotopic lesion, both at 8 and 15 days post-injection.  
These correspond to known time points in which there are both chondrogenic and 
osteogenic cells, which is why 10.5d was the most convenient time point to harvest 
tissue to analyze Tie2 reporter cell contribution to cartilage and bone within the 
lesion. The results of GFP+ cells of endothelial origin versus GFP+ cells of non-
endothelial origin are discussed in the next section. 
 
Fig. 6 BMP2-induced HO in a mouse TA. Two time points, 8d and 15d, demonstrate the lesion’s 
progression through the classic endochondral ossification pathway (A) A significant heterotopic 
lesion (dashed oval) is visible, shown here 15d after ossification was induced.  (B,C) Hemotoxylin and 
eosin (H&E) stained sections to show histology of a lesion 8d and 15d after ossification was induced.  
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(B) 8d lesions are well representative of cartilage (C), while (C) 15d lesions are well representative of 
bone (B). (Wosczyna et. al, 2012) 
 
IV. Tie2+ Progenitors are a Major Contributor to Heterotopic 
Ossification and are of Non-Endothelial Origin  
The heterotopic lesions within the TA muscles of the SCID mice were isolated 
by dissection, frozen for preservation, and sectioned onto slides.  Sections were 
analyzed via immunofluorescence to determine if either cell population contributed 
significantly to ossification in the lesion. Sox9 and Osterix staining was employed to 
label cartilage and bone, respectively.   In addition, CD31 staining was used to 
identify reporter cell contribution to vasculature of the lesion. The GFP+/CD31- 
population contributed to both chondrogenic (Sox9) and osteogenic (Osterix) cells 
of the BMP2-induced lesions (Fig. 7F-H, L-N).  It is important to note that nearly half 
of the cartilage and bone cells of the lesion remained unlabeled.  On the other hand, 
transplanted GFP+/CD31+ cells did not contribute to heterotopic cartilage or bone 
(Fig. 7C,E, I-K).   However, the GFP+/CD31+ cells did contribute to the vasculature of 
the lesion, consistent with their endothelial origin (Fig. 7C,E, I-K).  The evidence 
presented here demonstrates that there is a population of Tie2+ cells that are a 
significant progenitor of induced HO and are of non-endothelial origin.  
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Fig. 7 Confocal images of Sox9 (cartilage) and Osterix (bone) staining of induced heterotopic 
lesions 10.5d post-injection demonstrate that GFP+/CD31- cells from Tie2-Cre; R26NG/+ mice 
contribute to heterotopic lesions, while GFP+/CD31+ cells do not. (C-E, I-K) GFP+/CD31+ cells 
contribute to the vasculature of the lesion, evident from co-localization with CD31 staining, but do 
not co-localize with Sox9 or Osterix staining.   (F-H, L-N)  GFP+/CD31- cells co-localize with both 
Sox9 and Osterix staining. (Wosczyna et. al, 2012) 
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Discussion & Future Directions 
Vascular endothelium recently emerged as the best candidate progenitor cell of 
HO.  Other experiments have previously demonstrated the contribution of Tie2+ 
cells to induced heterotopic lesions (Lounev et al., 2009; Wosczyna et. al, 2012).   In 
order to trace this cell type, we employed the Cre/loxP lineage tracing system.  Mice 
were genotyped to determine which mice were successfully recombined by PCR and 
detection of fluorescence in tail clippings.  We confirmed the efficiency of this 
reporter by IHC, demonstrating the majority of cells labeled with GFP from the 
reporter mouse were also positive for an endothelial marker, CD31. We successfully 
isolated two cell populations by FACs: Tie2+/CD31+ (endothelial) and Tie2+/CD31- 
(non-endothelial), introduced the cell populations into SCID mice, and induced HO 
by BMP2 injection.  These lesions were analyzed by immunohistochemistry for both 
chondrogenic (Sox9) and osteogenic (Osterix) marker co-localization with the Tie2 
reporter cells.   
We demonstrated that a population of Tie2+, non-endothelial cells contributed 
to the heterotopic lesions in multiple phases of the classic endochondral pathway.  
The same methods of lineage tracing and analysis demonstrated that Tie2+, 
endothelial cells do not contribute to any phases of heterotopic skeletogenesis, but 
that these cells did contribute to the vascularization of the lesional tissue, consistent 
with their endothelial origin.  This data supports that there is a Tie2+, non-
endothelial progenitor cell in acquired HO.   
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These data contradict that of recent studies by Medici, et al that demonstrated 
progenitor cells of induced heterotopic cartilage and bone were of an endothelial 
origin (Medici, et al., 2010).  Although our work has demonstrated that both 
endothelial cells in their native in vivo context and FACS-purified endothelial cells 
do not contribute to heterotopic cartilage or bone, a level of ambiguity remains 
regarding conclusions to be drawn and require further investigation.  Cells 
expressing Tie2 have been demonstrated to contribute to all stages of BMP2-
induced heterotopic lesions, including the present study, but results presented by 
Lounev, et al. and Wosczyna, et al. conflict with that presented by Medici, et al. 
regarding the endothelial origin of these cells (Lounev, et al., 2009; Medici, et al., 
2010; Wosczyna, et al., 2012).  Although endothelium is the predominant cell type 
labeled by transgenic Tie2Cre; R26NG/+ mice, Tie2 is expressed in many non-
endothelial cell types.  The Medici, et al. experiments did not delineate between 
Tie2+ cells of endothelial and non-endothelial origin, assuming that all cells 
expressing Tie2 were of endothelial origin (Medici, et al., 2010).  In addition, an 
alternative transgenic mouse that labeled endothelium, VE-Cadherin-Cre, verified 
results that endothelial cells do not contribute to heterotopic cartilage and bone 
(Wosczyna, et al., 2012), leading us to conclude that endothelial cells are not a 
progenitor of bone and cartilage of HO.  
The determination of a major resident progenitor cell for HO provides valuable 
insight into this condition, but also opens the door to research to expand on this 
knowledge.  In order to facilitate further characterization of the cellular and 
molecular mechanisms by which these cells proceed, further work must be done to 
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characterize this cell population.  Others in our laboratory have already continued 
this work, determining this cell population expresses markers also expressed by 
mesenchymal progenitors (PDGFRα and Sca-1), showing a multipotent nature for 
these cell, and defining the anatomical location of these cells (Wosczyna, et al., 
2012).  These progenitor cells were found to be local residents of the skeletal 
muscle interstitium.  The same work in our laboratory has suggested these cells are 
not restricted to skeletal muscle though, as cells with a similar marker profile were 
isolated from mouse lung and kidney tissue (Woszcyna, et al., 2012).  The marker 
profile and anatomical location further distinguished these cells from many other 
potential progenitors, including pericytes and muscle-derived stem cells (Wosczyna, 
et al., 2012).  
Despite contribution by the Tie2+, non-endothelial cell population to the lesion, 
nearly half of the cartilage and bone cells were unlabeled.  The lack of GFP 
expression suggests that there may be two or more progenitor cell populations in 
addition to the one identified in the present study.  However, this is not definitive 
because the unlabeled cells could also be due to inefficient Cre-mediated 
recombination.  Further studies must be done to determine if any other cell 
populations are contributing to the heterotopic lesion, but the similar anatomical 
location, multipotent nature, and cell marker characterization of the GFP- cells from 
the lesional tissue to our population suggests that the inefficient Cre-mediated 
recombination is the most likely scenario (Wosczyna, et al., 2012).   
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Currently, all of the work to identify this cell type has been performed in a 
model of induced HO, most similar to acquired forms of the disease.  Similar studies 
must be done in a form that recapitulates the genetic forms, which would first 
require the mouse model with the mutation in the ACVR1/ALK2 receptor to be 
further established.  Use of this model would delineate any potential differences and 
could strengthen the results of this work.  However, the identification of the 
progenitors is a crucial step in establishing any future therapeutic agents or 
treatments for HO.  Eventually, further knowledge from this research into the 
initiation of these states will aid in the development of targeted therapies for the 
treatment and prevention of HO.  
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